These cuts to forensic research will not combat violent crime
By Susan R. Paisner,
Washington Post [Letter to the Editor]
| 07. 04. 2017
I suppose by this point I shouldn’t be surprised by anything the Trump administration does relating to science. But as a criminologist, I found myself stunned to read that Attorney General Jeff Sessions decided not to renew the National Commission on Forensic Science, which holds the responsibility for raising forensic standards [“Scientists defend panel on forensics,” PowerPost, June 30].
The article said, “Sessions, a former federal prosecutor, has said he wanted to ensure that Obama-era priorities did not counter Trump administration goals of combating violent crime and promoting police safety and morale.” Seriously? The administration’s 2018 budget would cut the National Institute of Standards and Technology’s funding by nearly 50 percent. NIST had just started a research effort to “increase the reliability of techniques that are used more than 100,000 times a year in U.S. crime labs.” This proposed budget would, among other things, eliminate a new research center and cut DNA-related and forensic programs.
Two questions, Mr. Sessions: First, are you actually stating that the Obama-era priorities were intended to increase violent crime and reduce police safety...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...